아미노펜타미드

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Glaucoma (absolute contraindication)
• Pyloric obstruction
• Hypersensitivity to anticholinergic drugs
• Tachycardias secondary to thyrotoxicosis or cardiac insufficiency
• Myocardial ischemia
• Unstable cardiac status during acute hemorrhage
• GI obstructive disease
• Paralytic ileus
• Severe ulcerative colitis
• Obstructive uropathy
• Myasthenia gravis (unless used to reverse adverse muscarinic effects)
• Known or suspected GI infections (e.g., parvovirus enteritis)

이상반응

• Dry mouth (xerostomia)
• Dry eyes (keratoconjunctivitis sicca)
• Blurred vision (mydriasis)
• Urinary hesitancy or retention
• Tachycardia
• Decreased GI motility (constipation/ileus)

약물 상호작용

• Antihistamines · May enhance the activity of anticholinergic derivatives
• Procainamide · May enhance the activity of anticholinergic derivatives
• Quinidine · May enhance the activity of anticholinergic derivatives
• Meperidine · May enhance the activity of anticholinergic derivatives
• Benzodiazepines · May enhance the activity of anticholinergic derivatives
• Phenothiazines · May enhance the activity of anticholinergic derivatives
• Primidone · May potentiate the adverse effects of anticholinergic derivatives
• Disopyramide · May potentiate the adverse effects of anticholinergic derivatives
• Nitrates · May potentiate the adverse effects of anticholinergic derivatives
• Corticosteroids (long-term use) · May increase intraocular pressure
• Nitrofurantoin · Anticholinergic derivatives may enhance actions
• Thiazide Diuretics · Anticholinergic derivatives may enhance actions
• Sympathomimetics · Anticholinergic derivatives may enhance actions

모니터링

• Clinical efficacy (resolution of spasms, vomiting, or diarrhea)
• Heart rate (monitor for tachycardia)
• Urination frequency and volume (monitor for urinary retention)
• Eye moisture and pupil size

과용량

No specific information was located regarding acute overdosage clinical signs or treatment for aminopentamide. Guidelines for atropine overdose may be applied: * **Decontamination:** If recent oral ingestion, empty gut contents and administer activated charcoal and saline cathartics. * **Supportive Care:** Treat clinical signs symptomatically. Fluid therapy and standard treatments for shock may be instituted. **Do not use phenothiazines** as they may contribute to anticholinergic effects. * **Antidote (Severe Cases):** The use of physostigmine is controversial and reserved for extreme agitation or life-threatening supraventricular/sinus tachycardias. Human pediatric dose (reasonable for small animals): 0.02 mg/kg slow IV, repeat q10 minutes until reversal of toxic effects. Physostigmine adverse effects (bronchoconstriction, bradycardia, seizures) may be treated with small doses of IV atropine.